MediGene’s strategic goal is to integrate all core areas of modern drug development into the company, from research on novel therapeutic concepts to the development and marketing of drugs. In this way we will participate in each step of the value chain. Major components of this strategy are already in place: MediGene is the first German biotechnology company with two drugs on the market which are distributed by partner companies. Medium-term MediGene plans to start own sales activities. MediGene has several drug candidates in different phases of clinical development, and possesses proprietary technologies for drug discovery and development that feed MediGene’s own product pipeline and are also available for partnerships. The revenues from drug sales will help to finance other research and development projects.
In the long term it will be very important for MediGene to further develop its innovative technologies, and to bring competitive drugs to the market. This may be accomplished on the basis of our own resources or through acquisitions, licensing, or by means of partnerships with other companies.
|
